Please ensure Javascript is enabled for purposes of website accessibility

Moderna Coronavirus Vaccine Approved in Europe

By Eric Volkman - Jan 6, 2021 at 3:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The vaccine can now be distributed and administered throughout the 27-country European Union.

Less than a month after winning emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its coronavirus vaccine, Moderna (MRNA 0.70%) has scored another major regulatory nod.

On Wednesday, the company announced that the European Commission -- the executive arm of the 27-country European Union (EU) -- granted conditional marketing authorization (CMA) for the company's mRNA-1273.

Moderna's vaccine is now authorized for use against the coronavirus in four jurisdictions. Besides the EU and the U.S., it has also been cleared in Canada and Israel.

The EU currently has a confirmed order totaling 160 million doses of Moderna's vaccine. The company said in its announcement that the first deliveries of these will occur next week.

Child getting a jab from a medical professional.

Image source: Getty Images.

Referring to the European Medicines Agency (EMA) and one of its key advisory bodies, Moderna CEO Stephane Bancel was quoted by the company as saying that "The EMA and the Committee for Medicinal Products for Human Use reviewers, working over the holidays, provided a thorough review and comprehensive guidance as we worked together to achieve this authorization."

"I am proud of the role Moderna has been able to play globally in helping to address this pandemic," he added.

The new authorization, while widely expected, is nevertheless a triumph for Moderna. The EU is a massive political and social block home to 446 million souls, a tally that dwarfs even the populous U.S. Meanwhile, the company has manufacturing capacity sufficient for a quick and wide rollout throughout Europe.

Investors are clearly happy about the news. In mid-afternoon trading Wednesday, Moderna was far outpacing the rise of the S&P 500, with the stock up by more than 6%.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$144.27 (0.70%) $1.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.